Literature DB >> 25972231

Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice.

Tadasuke Komori1, Minoru Tanaka, Hiroto Furuta, Takashi Akamizu, Atsushi Miyajima, Yoshihiro Morikawa.   

Abstract

AIMS/HYPOTHESIS: Obesity and insulin resistance are closely associated with adipose tissue dysfunction caused by the abnormal recruitment of inflammatory cells, including macrophages. Oncostatin M (OSM), a member of the IL-6 family of cytokines, plays important roles in a variety of biological functions including the regulation of inflammatory responses. In previous reports, we have demonstrated that mice deficient in the OSM receptor β subunit show obesity, adipose tissue inflammation, insulin resistance and hepatic steatosis, all of which are exacerbated by feeding the mice a high-fat diet. These results prompted us to test the therapeutic effects of OSM on obesity-induced metabolic disorders using mouse models of obesity.
METHODS: In diet-induced obese and ob/ob mice, metabolic variables were assessed physiologically, histologically and biochemically after the intraperitoneal injection of recombinant mouse OSM twice a day for 1 week.
RESULTS: Treatment with OSM improved obesity, adipose tissue inflammation, insulin resistance and hepatic steatosis in both mouse models. Although OSM reduced food intake, such therapeutic effects of OSM were observed even under pair-feeding conditions. Functionally, OSM directly changed the phenotype of adipose tissue macrophages from M1 type (inflammatory) to M2 type (anti-inflammatory). In the liver, OSM suppressed the expression of genes related to fatty acid synthesis and increased the expression of genes related to fatty acid oxidation. Furthermore, OSM decreased lipid absorption and increased the expression of active glucagon-like peptide-1 in the intestine. CONCLUSIONS/
INTERPRETATION: We showed that OSM is a novel candidate to act as a powerful therapeutic agent for the treatment of obesity-induced metabolic disorders.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25972231     DOI: 10.1007/s00125-015-3613-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  28 in total

1.  Thioesterase superfamily member 2/acyl-CoA thioesterase 13 (Them2/Acot13) regulates hepatic lipid and glucose metabolism.

Authors:  Hye Won Kang; Michele W Niepel; Shuxin Han; Yuki Kawano; David E Cohen
Journal:  FASEB J       Date:  2012-02-17       Impact factor: 5.191

Review 2.  Type 2 diabetes as an inflammatory disease.

Authors:  Marc Y Donath; Steven E Shoelson
Journal:  Nat Rev Immunol       Date:  2011-01-14       Impact factor: 53.106

Review 3.  Obesity, inflammation, and liver cancer.

Authors:  Beicheng Sun; Michael Karin
Journal:  J Hepatol       Date:  2011-11-25       Impact factor: 25.083

Review 4.  Abdominal obesity and metabolic syndrome.

Authors:  Jean-Pierre Després; Isabelle Lemieux
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

5.  Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.

Authors:  Ffolliott M Fisher; Patricia C Chui; Patrick J Antonellis; Holly A Bina; Alexei Kharitonenkov; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Diabetes       Date:  2010-08-03       Impact factor: 9.461

6.  Prostaglandin E2 is a novel inducer of oncostatin-M expression in macrophages and microglia.

Authors:  Pavle Repovic; Etty N Benveniste
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

7.  Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals.

Authors:  David Patsouris; Ping-Ping Li; Divya Thapar; Justin Chapman; Jerrold M Olefsky; Jaap G Neels
Journal:  Cell Metab       Date:  2008-10       Impact factor: 27.287

Review 8.  Oncostatin M, a multifunctional cytokine.

Authors:  M Tanaka; A Miyajima
Journal:  Rev Physiol Biochem Pharmacol       Date:  2003-06-17       Impact factor: 5.545

Review 9.  Lipid accumulation in non-adipose tissue and lipotoxicity.

Authors:  N A van Herpen; V B Schrauwen-Hinderling
Journal:  Physiol Behav       Date:  2007-12-05

10.  An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice.

Authors:  William L Holland; Andrew C Adams; Joseph T Brozinick; Hai H Bui; Yukiko Miyauchi; Christine M Kusminski; Steven M Bauer; Mark Wade; Esha Singhal; Christine C Cheng; Katherine Volk; Ming-Shang Kuo; Ruth Gordillo; Alexei Kharitonenkov; Philipp E Scherer
Journal:  Cell Metab       Date:  2013-05-07       Impact factor: 27.287

View more
  6 in total

1.  Loss of Oncostatin M Signaling in Adipocytes Induces Insulin Resistance and Adipose Tissue Inflammation in Vivo.

Authors:  Carrie M Elks; Peng Zhao; Ryan W Grant; Hardy Hang; Jennifer L Bailey; David H Burk; Margaret A McNulty; Randall L Mynatt; Jacqueline M Stephens
Journal:  J Biol Chem       Date:  2016-06-20       Impact factor: 5.157

Review 2.  Review: the Roles and Mechanisms of Glycoprotein 130 Cytokines in the Regulation of Adipocyte Biological Function.

Authors:  Dufang Ma; Yong Wang; Guofeng Zhou; Yongcheng Wang; Xiao Li
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

3.  Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis.

Authors:  Ehab A Ayaub; Anisha Dubey; Jewel Imani; Fernando Botelho; Martin R J Kolb; Carl D Richards; Kjetil Ask
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

4.  Inflammatory and anti-inflammatory markers in plasma: from late pregnancy to early postpartum.

Authors:  Emma Bränn; Åsa Edvinsson; Anna Rostedt Punga; Inger Sundström-Poromaa; Alkistis Skalkidou
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

5.  Oncostatin M promotes lipolysis in white adipocytes.

Authors:  Pim P van Krieken; Julian Roos; Pamela Fischer-Posovszky; Stephan Wueest; Daniel Konrad
Journal:  Adipocyte       Date:  2022-12       Impact factor: 4.534

6.  Essential roles of oncostatin M receptor β signaling in renal crystal formation in mice.

Authors:  Shimpei Yamashita; Tadasuke Komori; Yasuo Kohjimoto; Atsushi Miyajima; Isao Hara; Yoshihiro Morikawa
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.